JPRN-jRCT1080222532未知4 期
A Long-Term Clinical Study of TS-071 as Combination Therapy With GLP-1 Receptor Agonist in Patients With Type 2 Diabetes Mellitus
Taisho Pharmaceutical co., LTD0 个研究点目标入组 70 人开始时间: 2014年6月19日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Type 2 diabetes mellitus
- •- Has been receiving treatment with GLP-1 receptor agonist monotherapy at a fixed dose within the limit of approved continuously for more than 8 weeks.
排除标准
- •- Having non-type 2 diabetes mellitus.
- •- Having critical Heart Disease, other ciruculatory disease, cerebrovascular disorder, pancreatic disease and hematologic disease.
研究者
相似试验
未知
4 期
A Long-Term Clinical Study of TS-071 as Combination Therapy in Patients With Type 2 Diabetes on insulin therapyType 2 Diabetes MellitusJPRN-jRCT1080222531Taisho Pharmaceutical co., LTD225
未知
Unknown
A Long-Term Clinical Study of TS-071 as Combination Therapy With Glimepiride in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusJPRN-jRCT2080221468Taisho Pharmaceutical co., LTD225
未知
Unknown
A Long-Term Clinical Study of TS-071 as Combination Therapy With Oral Antidiabetic in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusJPRN-jRCT2080221469Taisho Pharmaceutical co., LTD450
未知
Unknown
A Long-Term Clinical Study of TS-071 as Monotherapy in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusJPRN-jRCT2080221470Taisho Pharmaceutical co., LTD300
未知
4 期
Clinical Pharmaclogical study of TS-071 in Patient With Type 2 Diabetetes Mellitus(Evaluation of glycemic variability using continuous glucose monitoring)Type 2 Diabetes MellitusJPRN-jRCT1080222497Taisho Pharmaceutical co., LTD40